Monoclonal Antibodies
JNJ-67856633 for Lymphoma and Leukemia
This trial tests JNJ-67856633, an oral drug, in patients with certain blood cancers that have returned or resisted treatment. The drug works by blocking a protein that helps cancer cells grow. The study aims to find the safest dose and see if the drug is effective.
Kinase Inhibitor
Triple Drug Therapy for Chronic Lymphocytic Leukemia
This trial is testing a new combination of drugs to treat leukemia. The drugs are ibrutinib, fludarabine, and pembrolizumab. The trial is open to patients with leukemia who have not responded to other treatments.
Popular Filters
Trials for CLL Patients
Monoclonal Antibodies
ONO-7018 for Non-Hodgkin's Lymphoma and Chronic B-Cell Leukemia
This trial is testing ONO-7018, a new drug designed to treat certain blood cancers that have not responded to other treatments. It works by blocking a protein that cancer cells need to grow. The study aims to find the best dose and check the drug's safety and effectiveness.
Monoclonal Antibodies
JNJ-80948543 for Lymphoma and Leukemia
This trial tests JNJ-80948543, a new medicine that helps the immune system fight B-cell non-Hodgkin lymphoid malignancies. It works by connecting immune cells to cancer cells, aiding in their destruction. The study aims to find the best dose and schedule while monitoring safety and effectiveness over an extended period.
LOXO-338 for Blood Cancers
This trial is testing a new drug, LOXO-338, to treat advanced blood cancer in patients who haven't responded to standard treatments. If effective alone, it will also be tested with another drug, pirtobrutinib, to see if the combination works better.
MALT1 Inhibitor
JNJ-67856633 + Ibrutinib for Lymphoma and Leukemia
This trial is testing two drugs, JNJ-67856633 and ibrutinib, to find the safest and most effective dose for treating certain blood cancers. It targets patients with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), who may not respond well to standard treatments. These drugs work by blocking proteins that help cancer cells grow.
Monoclonal Antibodies
JNJ-75348780 for Lymphoma and Leukemia
This trial tests JNJ-75348780, a new medicine that helps the immune system fight blood cancers in patients whose cancers have returned or did not respond to other treatments. It works by connecting immune cells to cancer cells, helping the immune system attack the cancer.
Monoclonal Antibodies
JNJ-64264681 for Non-Hodgkin's Lymphoma and Leukemia
This trial is testing a new drug called JNJ-64264681 to find the best dose and ensure it is safe. It focuses on patients with specific blood cancers, namely B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The drug aims to attack and kill the cancer cells in these patients.
Trials for Follicular Lymphoma Patients
Monoclonal Antibodies
ONO-7018 for Non-Hodgkin's Lymphoma and Chronic B-Cell Leukemia
This trial is testing ONO-7018, a new drug designed to treat certain blood cancers that have not responded to other treatments. It works by blocking a protein that cancer cells need to grow. The study aims to find the best dose and check the drug's safety and effectiveness.
Monoclonal Antibodies
JNJ-80948543 for Lymphoma and Leukemia
This trial tests JNJ-80948543, a new medicine that helps the immune system fight B-cell non-Hodgkin lymphoid malignancies. It works by connecting immune cells to cancer cells, aiding in their destruction. The study aims to find the best dose and schedule while monitoring safety and effectiveness over an extended period.
LOXO-338 for Blood Cancers
This trial is testing a new drug, LOXO-338, to treat advanced blood cancer in patients who haven't responded to standard treatments. If effective alone, it will also be tested with another drug, pirtobrutinib, to see if the combination works better.
MALT1 Inhibitor
JNJ-67856633 + Ibrutinib for Lymphoma and Leukemia
This trial is testing two drugs, JNJ-67856633 and ibrutinib, to find the safest and most effective dose for treating certain blood cancers. It targets patients with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), who may not respond well to standard treatments. These drugs work by blocking proteins that help cancer cells grow.
Monoclonal Antibodies
JNJ-75348780 for Lymphoma and Leukemia
This trial tests JNJ-75348780, a new medicine that helps the immune system fight blood cancers in patients whose cancers have returned or did not respond to other treatments. It works by connecting immune cells to cancer cells, helping the immune system attack the cancer.
Monoclonal Antibodies
JNJ-64264681 for Non-Hodgkin's Lymphoma and Leukemia
This trial is testing a new drug called JNJ-64264681 to find the best dose and ensure it is safe. It focuses on patients with specific blood cancers, namely B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The drug aims to attack and kill the cancer cells in these patients.
Trials for CD19 Positive Patients
Monoclonal Antibodies
Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia
This trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Immunomodulatory Agent
Triple Therapy for CLL/SLL
This trial is studying the side effects and best dose of lenalidomide when given with ibrutinib and rituximab to treat patients with CLL or SLL that has come back, is refractory, has spread, or cannot be removed by surgery.
Trials for CD20 Positive Patients
Monoclonal Antibodies
Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia
This trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Immunomodulatory Agent
Triple Therapy for CLL/SLL
This trial is studying the side effects and best dose of lenalidomide when given with ibrutinib and rituximab to treat patients with CLL or SLL that has come back, is refractory, has spread, or cannot be removed by surgery.
Monoclonal Antibodies
Atezolizumab + BTCT4465A (Mosunetuzumab) for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
This trial is testing a new drug called Mosunetuzumab, both alone and with another drug called atezolizumab, in patients with blood cancers that have not responded to other treatments. These drugs work by helping the immune system find and destroy cancer cells. Atezolizumab is a medication that has been approved for use in various cancers, including breast cancer, and has shown effectiveness when combined with other treatments.
BTK Inhibitor
Acalabrutinib for Chronic Lymphocytic Leukemia
This trial is testing a new medication, acalabrutinib, to see if it is safe and effective in treating people with chronic lymphocytic leukemia. The trial will last for approximately 72 months and will enroll 600 participants.
B-cell lymphoma-2 (BCL-2) inhibitor
Venetoclax + Ibrutinib + Obinutuzumab for Chronic Lymphocytic Leukemia
This trial is testing a new anti-cancer drug (venetoclax) to see if it can help treat patients with chronic lymphocytic leukemia who have not received previous treatment. The drug is being added to the usual treatment of ibrutinib and obinutuzumab. The trial will also investigate whether patients who receive all three treatments and have no detectable chronic lymphocytic leukemia after one year of treatment, can stop taking ibrutinib.
Phase 3 Trials
Kinase Inhibitor
Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab for Chronic B-Cell Leukemia
This trial is comparing two treatments for leukemia, one with ibrutinib and venetoclax, and the other with obinutuzumab and chlorambucil. The goal is to see which of these treatments results in better progression-free survival, as assessed by an independent review committee.
Monoclonal Antibodies
Nemtabrutinib + Venetoclax for Chronic Lymphocytic Leukemia
This trial tests a new drug (nemtabrutinib) with an existing one (venetoclax) in patients with CLL or SLL who haven't responded to other treatments. The drugs work together to stop cancer growth and kill cancer cells. Venetoclax is a selective Bcl-2 inhibitor approved for treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Bruton's Tyrosine Kinase (BTK) Inhibitor
Ibrutinib + Rituximab for Chronic Lymphocytic Leukemia
This trial is studying ibrutinib and rituximab compared to fludarabine phosphate, cyclophosphamide, and rituximab to see which works better in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Monoclonal Antibodies
Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia
This trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Monoclonal Antibodies
Obinutuzumab + Venetoclax vs. Chlorambucil for Chronic Lymphocytic Leukemia
This trial is testing a new combination of drugs for people with CLL and other medical conditions. The trial will last about a year, with follow-up for up to 9 years.
Trials With No Placebo
Monoclonal Antibodies
ONO-7018 for Non-Hodgkin's Lymphoma and Chronic B-Cell Leukemia
This trial is testing ONO-7018, a new drug designed to treat certain blood cancers that have not responded to other treatments. It works by blocking a protein that cancer cells need to grow. The study aims to find the best dose and check the drug's safety and effectiveness.
Monoclonal Antibodies
JNJ-80948543 for Lymphoma and Leukemia
This trial tests JNJ-80948543, a new medicine that helps the immune system fight B-cell non-Hodgkin lymphoid malignancies. It works by connecting immune cells to cancer cells, aiding in their destruction. The study aims to find the best dose and schedule while monitoring safety and effectiveness over an extended period.
LOXO-338 for Blood Cancers
This trial is testing a new drug, LOXO-338, to treat advanced blood cancer in patients who haven't responded to standard treatments. If effective alone, it will also be tested with another drug, pirtobrutinib, to see if the combination works better.
MALT1 Inhibitor
JNJ-67856633 + Ibrutinib for Lymphoma and Leukemia
This trial is testing two drugs, JNJ-67856633 and ibrutinib, to find the safest and most effective dose for treating certain blood cancers. It targets patients with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), who may not respond well to standard treatments. These drugs work by blocking proteins that help cancer cells grow.
Monoclonal Antibodies
JNJ-75348780 for Lymphoma and Leukemia
This trial tests JNJ-75348780, a new medicine that helps the immune system fight blood cancers in patients whose cancers have returned or did not respond to other treatments. It works by connecting immune cells to cancer cells, helping the immune system attack the cancer.
Monoclonal Antibodies
JNJ-64264681 for Non-Hodgkin's Lymphoma and Leukemia
This trial is testing a new drug called JNJ-64264681 to find the best dose and ensure it is safe. It focuses on patients with specific blood cancers, namely B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The drug aims to attack and kill the cancer cells in these patients.
View More Related Trials
Frequently Asked Questions
Introduction to chronic lymphocytic leukemia
What are the top hospitals conducting chronic lymphocytic leukemia research?
When it comes to cutting-edge clinical trials for chronic lymphocytic leukemia (CLL), several hospitals across the United States are leading the charge. In Houston, M D Anderson Cancer Center shines with 11 ongoing CLL trials and an impressive track record of 48 completed trials dedicated to this condition. Their commitment dates back to their first recorded CLL trial in 1998, demonstrating long-standing expertise in tackling this challenging disease. Similarly, Memorial Sloan Kettering Cancer Center in New york boasts seven active CLL trials and a total of 35 previously conducted studies since embarking on their first trial in 2005.
Moving westward to Seattle, the Fred Hutchinson Cancer Research Center is making significant strides with six active clinical trials focused on CLL. They have contributed extensively to understanding and treating this blood cancer over the years, having initiated their inaugural trial as early as 1995. Meanwhile, on the West Coast in Duarte, California, both City of Hope Comprehensive Cancer Center and its counterpart City of Hope are actively engaged in advancing knowledge about CLL through innovative research protocols. The former currently has six ongoing clinical trials while having undertaken thirteen previous investigations since recording its first CLL trial in 2000. On the other hand, City of Hope contributes five active clinical tests towards finding better treatment options for patients battling this disease; they started conducting these insightful inquiries only fourteen years ago with a debut experiment logged under "chronic lymphocytic leukemia" throughout all-time tally reaching twenty-one.
These top-tier medical institutions represent beacons of hope for individuals affected by chronic lymphocytic leukemia. Through constant dedication and groundbreaking research efforts at these renowned hospitals spanning across different corners of America - from bustling cities like Houston and New York to picturesque locations like Seattle and Duarte - we can remain optimistic that breakthroughs are within reach that will pave new pathways towards more effective treatments for those living with this challenging form of blood cancer
Which are the best cities for chronic lymphocytic leukemia clinical trials?
When it comes to chronic lymphocytic leukemia clinical trials, several cities have emerged as key players in advancing research and treatment options. Denver, Colorado leads the way with 43 active trials focusing on Ibrutinib, Quality-of-Life Assessment, and other innovative approaches. New york, New York and Houston, Texas follow closely behind with 32 ongoing studies exploring promising treatments like Pirtobrutinib, JNJ-80948543, JNJ-67856633, and Ibrutinib. Anchorage, Alaska also makes a mark with 25 active trials investigating Ibrutinib and Quality-of-Life Assessment. Lastly, Duarte California contributes to advancements through its 20 ongoing trials studying therapies such as JCAR017 (lisocabtagene maraleucel), ibrutinib, and JNJ-80948543. Together these cities offer individuals fighting chronic lymphocytic leukemia access to cutting-edge clinical trials that pave the way for improved care outcomes.
Which are the top treatments for chronic lymphocytic leukemia being explored in clinical trials?
Exciting advancements in the realm of chronic lymphocytic leukemia (CLL) are taking shape through rigorous clinical trials. Leading the charge is ibrutinib, showcasing its potential in 10 active CLL trials and accumulating an impressive total of 87 all-time trials since its introduction in 2012. Not far behind is acalabrutinib, making waves with eight ongoing clinical trials and a solid foundation of 32 previous CLL studies since its debut in 2014. Venetoclax also shines as a promising treatment option, currently being explored in four active CLL trials, alongside an extensive history of 78 all-time investigations starting from 2012. Another contender on the forefront is pirtobrutinib—although relatively new—with four active and eight all-time CLL trials recorded since it was first listed in 2018. These treatments hold immense potential to transform the landscape for patients fighting against this challenging disease.
What are the most recent clinical trials for chronic lymphocytic leukemia?
Recent clinical trials for chronic lymphocytic leukemia offer new hope and potential treatment options. One trial explores the use of a combination treatment consisting of tafasitamab, obinutuzumab, and acalabrutinib in Phase 1. Another study investigates the efficacy of nemtabrutinib combined with Venetoclax in Phase 3. Additionally, an ongoing Phase 2 trial called Arm I (GEO-CM04S1) aims to evaluate a specific treatment approach for this type of leukemia. Furthermore, another promising Phase 2 trial examines the effectiveness of combining tafasitamab and zanubrutinib as a therapeutic option. Lastly, Acalabrutinib is being studied in a separate Phase 2 trial as a potential targeted therapy for chronic lymphocytic leukemia patients. These advancements hold great promise for improving outcomes and quality of life for those affected by this challenging disease.
What chronic lymphocytic leukemia clinical trials were recently completed?
Recent advancements in clinical trials for chronic lymphocytic leukemia (CLL) have been promising, offering hope to patients battling this complex disease. Noteworthy completed trials include the investigation of PBCAR20A by Precision BioSciences, Inc., concluded in March 2020. Mayo Clinic also achieved significant progress with their trial on Nab-paclitaxel/Rituximab-coated Nanoparticle AR160, finalized in April 2019. Additionally, the University of Rochester successfully completed a trial examining the efficacy of the Shingrix vaccine in February 2019. These innovative studies highlight the commitment and dedication of researchers towards improving CLL treatment options and ultimately enhancing patient outcomes.